Article PDF
References
Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104:575–81.
Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41:266–70.
Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006; 104:631–3.
Miller RD. Sugammadex: an opportunity to change the practice of anesthesiology?Anesth Analg 2007; 104:477–8.
Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99:1080–5.
Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98:302–16.
Plaud B, Proost JH, Wierda JM, Barre J, Debaene B, Meistelman Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther 1995; 58:185–91.
Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99:632–7.
Gijsenbergh F, Ramael S, Houwing N, van IerselT. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103:695–703.
Sorgenfrei IF, Norrild Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dosefinding and safety study. Anesthesiology 2006; 104:667–74.
Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106:935–43.
Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104:582–4.
Author information
Authors and Affiliations
Additional information
The author has received honoraria and research grants from Organon Inc, the manufacturer of sugammadex.
L’auteur a re u des honoraires et des subventions de recherche d’Organon Inc, le fabricant du sugammadex.
Rights and permissions
About this article
Cite this article
Donati, F. Sugammadex: an opportunity for more thinking or more cookbook medicine?. Can J Anesth 54, 689–695 (2007). https://doi.org/10.1007/BF03026865
Issue Date:
DOI: https://doi.org/10.1007/BF03026865